Clinical application of CDK4/6 SMIs appears to display weak effects in some tumors (including colorectal cancer, triple-negative breast cancer, melanomas, etc.), where innate or rapid acquisition of resistance may happen [29]. The gene discussed is CDK4; the disease is melanoma.